Boston Scientific

What Boston Scientific does

Boston Scientific Corporation (NYSE: BSX) is a publicly traded global medical technology company founded in 1979 and headquartered in Marlborough, Massachusetts, that designs, develops, manufactures, and markets minimally invasive medical devices across 16 specialty areas including electrophysiology, interventional cardiology, structural heart, peripheral vascular, cardiac rhythm management (CRM), neuromodulation, pain management, urology and pelvic health, endoscopy, interventional radiology, and critical care. The portfolio includes differentiated platforms such as FARAPULSE pulsed field ablation for atrial fibrillation, WATCHMAN FLX left atrial appendage closure, HeartLogic AI-enabled heart failure diagnostic on the LATITUDE NXT Remote Patient Management System, ECAP-guided WaveWriter Alpha spinal cord stimulation, BrainSense Vercise Genus deep brain stimulation, the EXALT Model D single-use duodenoscope, AGENT drug-coated balloon, and SYNERGY XD coronary stents, complemented by acquired franchises including Axonics sacral neuromodulation, Intracept basivertebral nerve ablation (Relievant), eCoin tibial nerve stimulation (Valencia Technologies), and the THUNDERBOLT computer-assisted vacuum thrombectomy system (Penumbra).

The company generates revenue primarily through one-time sales of capital and implantable medical devices to hospitals, ambulatory surgery centers, and physicians globally, layered with recurring revenue from consumables and disposable accessories (catheters, ablation catheters, leads, single-use scopes) and multi-year replacement cycles for long-lived implants such as pacemakers, ICDs, and neuromodulation IPGs. Pricing is quote-based and negotiated through GPO and IDN contracts rather than publicly disclosed. Boston Scientific distributes predominantly through a direct global field salesforce spanning more than 65 countries, supported by the EDUCARE clinical education platform, industry conferences (e.g., Bernstein Strategic Decisions, HRS, DDW, AUA), patient-facing disease awareness websites, and direct ecommerce ordering for selected products.

Boston Scientific reported FY2025 revenue of approximately $20.1 billion (versus $16.7 billion in FY2024) and Q1 2026 revenue of $5.20 billion (+11.6% YoY), with EBITDA of $5.34 billion and net income of $2.90 billion in FY2025. The company's near-term strategy is dominated by an aggressive acquisition cadence, including the $14.5 billion Penumbra close in January 2026 and the $1.5 billion MiRus strategic equity investment plus TAVR option in May 2026, alongside a $2 billion accelerated share repurchase, while navigating material headwinds including a slowing U.S. electrophysiology business, an FDA Class I recall of Accolade pacemakers in May 2026, securities fraud class action lawsuits, and a 46%-55% trailing-year share price decline.

Name

Boston Scientific

Legal name

Boston Scientific Corporation

Website

https://bostonscientific.com

Company type

Public

Founded year

1979

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Boston Scientific is a global medical technology company (NYSE: BSX) that designs, manufactures, and markets minimally invasive medical devices across cardiology, neuromodulation, endoscopy, urology/pelvic health, peripheral vascular, and structural heart, serving hospitals, IDNs, and physicians in 65+ countries.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Minimally invasive medical devices
• Cardiac rhythm management
• Interventional cardiology devices
• Neuromodulation systems
• Structural heart therapies

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Hardware Sales: Primary revenue stream from one-time sales of implanted and capital medical devices across cardiology, peripheral vascular, CRM, neuromodulation, endoscopy, and urology/pelvic health franchises to hospitals, ambulatory surgery centers, and physicians globally.
2. Recurring Implantable Device Revenue: Replacement-driven recurring revenue from CRM (pacemakers, ICDs), neuromodulation implants (IPG replacements), and other long-lived implantables that require periodic replacement over multi-year cycles.
3. Consumables and Disposable Accessories: High-margin recurring revenue from single-use catheters, ablation catheters, leads, guidewires, and other consumables that pair with capital and implantable devices (e.g., FARAPULSE FARAWAVE catheters, single-use duodenoscopes).
4. Professional Services and Clinical Education: Revenue and value-add from physician training, proctoring, and clinical education services (e.g., EDUCARE platform) supporting product adoption.
5. Licensing and Royalty Income: Royalty and licensing revenue from intellectual property licensed to third parties, including catheter, imaging, and surgical technology.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Boston Scientific designs, manufactures, and sells a broad portfolio of minimally invasive medical devices across 16 medical specialties, including electrophysiology and pulsed field ablation (FARAPULSE), left atrial appendage closure (WATCHMAN FLX Pro), cardiac rhythm management (RESONATE CRT-D, ACCOLADE pacemakers, EMBLEM S-ICD), neuromodulation (WaveWriter Alpha SCS, Vercise Genus DBS, Axonics SNM), interventional cardiology (SYNERGY XD, AGENT DCB), structural heart (SENTINEL CPS), peripheral vascular (Eluvia, EKOS, SEISMIQ IVL, RANGER DCB), urology and pelvic health (Rezum, GreenLight, AMS 700/800, SpaceOAR, LithoVue Elite), endoscopy (EXALT Model B, SpyGlass DS, AXIOS, OverStitch), and pain management (Intracept, Nalu PNS), supported by AI-enabled remote monitoring (HeartLogic, LATITUDE NXT, BodyGuardian 360). The company sells primarily to hospitals, integrated delivery networks, and specialty physicians through a global direct field salesforce, with recurring revenue from replacement implants and single-use consumables.

Product overview

Boston Scientific offers a unified multi-specialty medical device platform rather than a single product, organized across 16 medical specialties including Critical Care, Electrophysiology, Gastroenterology, Heart Failure, Interventional Cardiology, Neurological Surgery, Pain Management, Pelvic Health, Pulmonology, Structural Heart, Urology, and Vascular Surgery. The platform spans diagnostic, monitoring, ablation, neuromodulation, stent, and surgical device families, supplemented by acquired product lines including Watchman LAAC (WATCHMAN FLX Pro), HeartLogic heart failure diagnostic on the LATITUDE NXT Remote Patient Management System, FARAPULSE PFA system, Intracept basivertebral nerve ablation system (Relievant Medsystems), Nalu neurostimulation (Nalu Medical), Axonics sacral neuromodulation, OBSIDIO embolic (Obsidio), Lumenis CO2 laser systems, eCoin ITNS (Valencia Technologies), and Penumbra's THUNDERBOLT thrombectomy platform. Diagnostic and capital equipment offerings (OPAL HDx mapping system, MAESTRO 4000, INTELLAGEN, LABSYSTEM PRO, iLAB ultrasound) and remote patient management (LATITUDE NXT, BodyGuardian 360, Heart Connect) tie the portfolio together, while therapy-specific devices (WaveWriter Alpha SCS, Vercise Genus DBS, SENTINEL CPS, AGENT DCB, SYNERGY XD, SEISMIQ IVL, SpaceOAR Hydrogel, EXALT Model B single-use bronchoscope, and the Pulse 120H/LithoVue Elite stone management line) address distinct clinical use cases within the broader platform.

Differentiator

Problem solved

Functional benefit

Brands

• WATCHMAN: Left Atrial Appendage Closure (LAAC) device platform including WATCHMAN FLX Pro, WATCHMAN FXD Curve and TruSteer access systems for non-valvular atrial fibrillation patients.
• FARAPULSE
• Vercise Genus
• WaveWriter Alpha
• Intracept
• SENTINEL
• EXALT
• Axonics
• Bulkamid
• Rezūm
• GreenLight
• AMS 700
• LithoVue Elite
• AGENT
• HeartLogic
• LATITUDE
• BodyGuardian
• SYNERGY
• LUX-Dx
• TheraSphere
• EKOS
• Eluvia
• Varithena
• Obsidio
• SpaceOAR
• eCoin
• Endura Life
• EMBOLD
• SEISMIQ
• SAFARI2

Products and services

• EXALT Model B Single-Use Bronchoscope Single-use bronchoscope designed for bedside ICU procedures, featuring powerful suction across all scope sizes, superior ergonomics, and best-in-class visualization, optimized for ICU and critical care use.
• WATCHMAN FLX Pro Left Atrial Appendage Closure Device FDA-approved LAAC device featuring HEMOCOAT Technology, designed to reduce thromboembolism risk in patients with non-valvular atrial fibrillation as an alternative to long-term anticoagulation.
• FARAPULSE Pulsed Field Ablation System Pulsed field ablation system for atrial fibrillation that selectively ablates myocardium to reduce risk of damage to surrounding tissue, delivers durable transmural PV lesions, adapts to variable patient anatomy, and visualizes workflow with integrated mapping and magnetically-tracked catheter.
• RESONATE HF CRT-D and RESONATE X4 CRT-D Cardiac resynchronization therapy defibrillators featuring HeartLogic Heart Failure Diagnostic, EnduraLife Battery Technology, ImageReady MR-Conditional technology, and SmartCRT Technology for managing heart failure patients.
• OPAL HDx Mapping System High-density mapping system providing integrated mapping for both RF and pulsed field ablation procedures, with enhanced access to the FARAPULSE PFA System and DIRECTSENSE technology for tissue resistivity and localized impedance measurement.
• LUX-Dx II+ Insertable Cardiac Monitor System Insertable cardiac monitor (loop recorder) using enhanced dual-stage algorithms that detect and verify arrhythmic data before sending results, with remote programming capability; monitors and records cardiac arrhythmias.
• EMBLEM MRI S-ICD System Subcutaneous implantable cardioverter-defibrillator that protects against sudden cardiac death without touching the heart, vasculature, or substernal space; the only subcutaneous ICD system of its kind.
• ACCOLADE and ESSENTIO Pacemakers Family of pacemakers delivering RightRate respiration-based pacing and daily remote monitoring for advanced pacemaker technology; subject to a 2026 FDA Class I recall correction for a software-related battery issue affecting certain ACCOLADE and cardiac resynchronization therapy pacemakers.

Quantifiable outcome

• 48M+ patients reached annually with Boston Scientific therapies
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability7 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered minor and flagship.

• MiRusminorStrategic or Co-development PartnerBoston Scientific made a strategic investment in MiRus with an option to acquire the company. The partnership expands Boston Scientific's footprint in structural heart and interventional technologies.
• PenumbraminorStrategic or Co-development PartnerBoston Scientific entered an option agreement with Penumbra related to its peripheral thrombectomy portfolio, exploring commercial and clinical synergies.
• Nalu MedicalminorStrategic or Co-development PartnerBoston Scientific acquired Nalu Medical to expand its neuromodulation portfolio with a differentiated, miniaturized implantable neurostimulator for chronic pain.
• Valencia TechnologiesminorStrategic or Co-development PartnerBoston Scientific acquired Valencia Technologies, adding a miniaturized, leadless neurostimulator for overactive bladder to its urology/pelvic health franchise.
• AxonicsflagshipStrategic or Co-development PartnerBoston Scientific completed the acquisition of Axonics, adding a differentiated rechargeable sacral neuromodulation system for overactive bladder, urinary retention, and fecal incontinence to its portfolio.
• SoniVieminorStrategic or Co-development PartnerBoston Scientific acquired SoniVie, expanding its interventional cardiology and renal denervation capabilities for treatment of hypertension.
• MedTech BreakthroughminorGTM or Marketing PartnerMedTech Breakthrough recognized Boston Scientific at its 10th Annual MedTech Breakthrough Awards program, providing industry visibility and third-party validation.

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Medtronic: Largest direct competitor across interventional cardiology, cardiac rhythm management, neuromodulation (pain and DBS), structural heart, and peripheral vascular. Operates with a comparable global field-sales model and similarly broad hospital and physician customer base.
• Abbott Laboratories: Direct competitor in electrophysiology (ablation catheters, mapping), structural heart, neuromodulation, and vascular devices. Competes head-to-head in CRM and cardiovascular franchises with similar hospital-channel GTM.
• Johnson & Johnson MedTech (Biosense Webster / DePuy / Ethicon): Direct competitor in electrophysiology via Biosense Webster (CARTO mapping and ablation catheters) and overlaps in interventional cardiology, surgical devices, and endoscopy; comparable multi-specialty medtech portfolio.
• Edwards Lifesciences: Direct competitor in structural heart (TAVR/TAVI), where BSX is building presence via the MiRus SIEGEL option, SENTINEL cerebral protection, and SAFARI2 guidewire; overlaps in heart failure management and critical care.

Broad incumbents

• Stryker: Broader medtech incumbent with overlapping surgical, endoscopy, and capital equipment footprints; competes with BSX's gastrointestinal surgery, ENT, and gynecology franchises and shares a hospital-channel go-to-market.
• Intuitive Surgical: Broad incumbent in robotic-assisted minimally invasive surgery, addressing overlapping procedural specialties (urology, gynecology, thoracic); competes for hospital capital budgets and procedural share against BSX's surgical and urology lines.
• Zimmer Biomet: Broad incumbent in musculoskeletal and surgical medtech with similar hospital-channel GTM; adjacent to BSX in interventional orthopedics (e.g., Intracept for vertebrogenic pain) and urology surgical devices.

Emerging players

• Inspire Medical Systems: Emerging neuromodulation competitor focused on hypoglossal nerve stimulation for obstructive sleep apnea; overlaps with BSX's neuromodulation franchise on physician call-point and implant economics.
• Inari Medical: Emerging thrombectomy and venous thromboembolism player whose flow-triever and clottrever devices compete with EKOS, Penumbra, and BSX's peripheral vascular portfolio for VTE procedure share.

Others

• Silk Road Medical: TCAR-focused neuro- and carotid-protection company that was acquired by BSX in 2024; referenced here as a now-integrated peer platform for transcarotid neuroprotection (ENROUTE) competing against broader carotid surgery alternatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bostonsci
• Facebookfacebook.com/BostonScientific
• LinkedInlinkedin.com/company/boston-scientific

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Subsidiaries16 records

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A67 records

Investments57 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boston Scientific